|
|
||||||||
1Department of Internal Medicine, 2Institute for Cardiovascular Research, 4Department of Nephrology, and 5Department of Clinical Chemistry, Vrije Universiteit Medical Center, 1081 HV Amsterdam; and 3Department of Internal Medicine, Amphia Hospital, 4800 RL Breda, The Netherlands
Submitted 28 October 2003 ; accepted in final form 25 March 2004
Hyperhomocysteinemia is a risk factor for cardiovascular disease and occurs frequently in end-stage renal disease (ESRD), but its pathogenesis is poorly understood. We aimed to evaluate one-carbon flux rates of methionine and homocysteine (Hcy) in ESRD patients and healthy controls. Transmethylation (TM), remethylation (RM), and transsulfuration (TS), as well as Hcy clearance by TS (i.e., TS/plasma total Hcy concentration) and by RM (i.e., RM/plasma total Hcy concentration) were evaluated in relation to body composition, vitamins, and S-adenosylhomocysteine (AdoHcy) and S-adenosylmethionine (AdoMet) levels. After a fixed protein diet for 3 days, primed-continuous infusion of [2H3-methyl-1-13C]methionine was performed in the postabsorptive state in 12 hemodialysis patients and 16 healthy volunteers. Hcy clearance by TS (80%, P < 0.001) and by RM (77%, P < 0.001) in ESRD patients was decreased compared with healthy controls. The absolute flux rates of TM (27%, P < 0.01) and RM (28%, P = 0.02) were lower in the ESRD patients. After adjustment for age, TS was not significantly reduced. Whole blood AdoHcy was significantly elevated in ESRD and was a significant determinant of TM (standardized
= 1.24, P = 0.01) and RM (standardized
= 1.43, P = 0.03). In conclusion, patients with ESRD have impaired Hcy clearance by TS and RM. Elevated whole blood AdoHcy levels are associated with impaired RM and TM flux rates in these patients, and AdoHcy may be a key regulatory compound in one-carbon flux.
stable isotopes; S-adenosylmethionine; transsulfuration; remethylation; transmethylation
This article has been cited by other articles:
![]() |
P. Stenvinkel and T. J. Ekstrom Epigenetics--a helpful tool to better understand processes in clinical nephrology? Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1493 - 1496. [Full Text] [PDF] |
||||
![]() |
K. T. Williams and K. L. Schalinske New Insights into the Regulation of Methyl Group and Homocysteine Metabolism J. Nutr., February 1, 2007; 137(2): 311 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Herrmann, O. Taban-Shomal, U. Hubner, M. Bohm, and W. Herrmann A review of homocysteine and heart failure Eur J Heart Fail, October 1, 2006; 8(6): 571 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. van Guldener Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1161 - 1166. [Full Text] [PDF] |
||||
![]() |
R. Fux, D. Kloor, M. Hermes, T. Rock, B. Proksch, A. Grenz, U. Delabar, R. Bucheler, S. Igel, K. Morike, et al. Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers Am J Physiol Renal Physiol, October 1, 2005; 289(4): F786 - F792. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |